Background: Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema and increased risk of infections, mainly due to its main mechanism of action, the non-selective modulation of sphingosine-1-phosphate receptor.
Methods and results: We report the baseline characteristics, effectiveness outcomes and adverse events of a prospective cohort of 177 patients with a median treatment duration of 24 months, in which four patients (2.3%) presented with otherwise non-provoked peripheral vascular events (PVE).
Conclusions: Further studies are still needed to evaluate the frequency and severity of PVE in fingolimod patients.
Keywords: Adverse events; Disease-modifying treatment; Fingolimod; Multiple sclerosis; Peripheral vascular events; Thrombosis.
Copyright © 2020 Elsevier B.V. All rights reserved.